PR115002 / Merna Therapeutics - LARVOL DELTA

Preclinical efficacy of PR115002, a novel sortilin-targeting peptide-drug conjugate, in platinum-resistant ovarian cancer. (ASCO 2025) - "The in vitro findings indicated that PR115002 exhibited specific binding affinity for human sortilin and displayed significant cytotoxicity against cell lines resistant to platinum-based therapies. Additionally, the in vivo results revealed the therapeutic efficacy of PR115002 in the context of platinum-resistant OC. Collectively, these findings provide a strong rationale for the continued development of PR115002 for use in patients with platinum-resistant OC."

Platinum resistant • Preclinical • Oncology • Ovarian Cancer • Solid Tumor • SORT1